{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:23:32Z","timestamp":1790659412209,"version":"4.1.0"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T00:00:00Z","timestamp":1776470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T00:00:00Z","timestamp":1776470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Ondokuz May\u0131s University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:title>Opinion statement<\/jats:title>\n                  <jats:p>We focus our second-line treatment strategy on biomarker-defined resistance mechanisms that emerge after progression on CDK4\/6 inhibitors. In our view, ESR1 mutation\u2013mediated resistance constitutes a biologically distinct phenotype of endocrine resistance rather than a simple treatment escape. Therefore, in patients with ESR1-mutated tumors, we strongly favor incorporating next-generation oral selective estrogen receptor degraders (SERDs), given their targeted mechanism, favorable tolerability, and efficacy following CDK4\/6 inhibition. For tumors harboring alterations in the PIK3CA\u2013AKT\u2013PTEN pathway, treatment selection is similarly biomarker driven. In patients with PIK3CA mutations, fulvestrant combined with alpelisib remains an effective option, though tolerability concerns often influence long-term adherence; accordingly, we increasingly prefer fulvestrant with capivasertib due to its activity across PIK3CA, AKT1, and PTEN alterations and its more manageable safety profile. When patients exhibit rapid progression, endocrine-independent biology, or aggressive visceral disease, we transition early to antibody\u2013drug conjugates such as trastuzumab deruxtecan or sacituzumab govitecan, which demonstrate superior outcomes compared with conventional chemotherapy in appropriately selected cases. Overall, an individualized, biomarker-driven approach remains central to optimizing therapeutic sequencing in advanced HR+ breast cancer.<\/jats:p>","DOI":"10.1007\/s11864-026-01391-3","type":"journal-article","created":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T10:13:35Z","timestamp":1776507215000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Beyond CDK4\/6 Inhibition: Current Strategies in Hormone Receptor-Positive Metastatic Breast Cancer"],"prefix":"10.1007","volume":"27","author":[{"given":"Bulent","family":"Cetin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilek","family":"Erdem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irem","family":"Karaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozge","family":"Gumusay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,18]]},"reference":[{"key":"1391_CR1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41523-023-00523-4","volume":"9","author":"R Patel","year":"2023","unstructured":"Patel R, Klein P, Tiersten A, Sparano JA. An emerging generation of endocrine therapies in breast cancer: a clinical perspective. NPJ Breast Cancer. 2023;9:20.","journal-title":"NPJ Breast Cancer"},{"key":"1391_CR2","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrclinonc.2015.117","volume":"12","author":"R Jeselsohn","year":"2015","unstructured":"Jeselsohn R, Buchwalter G, De Angelis C, Brown M, Schiff R. ESR1 mutations\u2014a mechanism for acquired endocrine resistance in breast cancer. Nat Rev Clin Oncol. 2015;12:573\u201383.","journal-title":"Nat Rev Clin Oncol"},{"key":"1391_CR3","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13058-021-01462-3","volume":"23","author":"JO Brett","year":"2021","unstructured":"Brett JO, Spring LM, Bardia A, Wander SA. ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer. Breast Cancer Res. 2021;23:85.","journal-title":"Breast Cancer Res"},{"key":"1391_CR4","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1200\/JCO.22.00338","volume":"40","author":"FC Bidard","year":"2022","unstructured":"Bidard FC, Kaklamani VG, Neven P, Streich G, Montero AJ, Forget F, et al. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. J Clin Oncol. 2022;40:3246\u201356.","journal-title":"J Clin Oncol"},{"key":"1391_CR5","doi-asserted-by":"publisher","first-page":"4299","DOI":"10.1158\/1078-0432.CCR-24-1073","volume":"30","author":"A Bardia","year":"2024","unstructured":"Bardia A, Cort\u00e9s J, Bidard FC, Neven P, Garcia-S\u00e1enz J, Aftimos P, et al. Elacestrant in ER+, HER2- Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4\/6 Inhibitor and in Clinical Subgroups. Clin Cancer Res. 2024;30:4299\u2013309.","journal-title":"Clin Cancer Res"},{"key":"1391_CR6","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa2410858","volume":"392","author":"KL Jhaveri","year":"2025","unstructured":"Jhaveri KL, Neven P, Casalnuovo ML, Kim SB, Tokunaga E, Aftimos P, et al. Imlunestrant with or without Abemaciclib in Advanced Breast Cancer. N Engl J Med. 2025;392:1189\u2013202.","journal-title":"N Engl J Med"},{"key":"1391_CR7","doi-asserted-by":"crossref","unstructured":"Curigliano G, O\u2019Shaughnessy J, Bidard FC, Kim S-B, Tokunaga E, Aftimos PG, et al. Patient-reported outcomes (PROs) in patients with ER+, HER2-advanced breast cancer (ABC) treated with imlunestrant, investigator\u2019s choice standard endocrine therapy, or imlunestrant+ abemaciclib: Results from the phase III EMBER-3 trial. Am Soc Clin Oncol. 2025.","DOI":"10.1200\/JCO.2025.43.16_suppl.1001"},{"key":"1391_CR8","doi-asserted-by":"crossref","unstructured":"Kalinsky K, Bianchini G, Hamilton EP, Graff SL, Park KH, Jeselsohn R, et al. Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2-advanced breast cancer following progression on a prior CDK4\/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial. Am Soc Clin Oncol. 2024.","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA1001"},{"key":"1391_CR9","doi-asserted-by":"publisher","first-page":"4173","DOI":"10.1200\/JCO.23.02733","volume":"42","author":"KL Jhaveri","year":"2024","unstructured":"Jhaveri KL, Lim E, Jeselsohn R, Ma CX, Hamilton EP, Osborne C, et al. Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia\/Ib EMBER Study. J Clin Oncol. 2024;42:4173\u201386.","journal-title":"J Clin Oncol"},{"key":"1391_CR10","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.annonc.2023.09.3104","volume":"34","author":"MP Goetz","year":"2023","unstructured":"Goetz MP, Bagegni NA, Batist G, Brufsky A, Cristofanilli MA, Damodaran S, et al. Lasofoxifene versus fulvestrant for ER+\/HER2- metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial. Ann Oncol. 2023;34:1141\u201351.","journal-title":"Ann Oncol"},{"key":"1391_CR11","doi-asserted-by":"publisher","first-page":"3759179","DOI":"10.1155\/2020\/3759179","volume":"2020","author":"EJ Anderson","year":"2020","unstructured":"Anderson EJ, Mollon LE, Dean JL, Warholak TL, Aizer A, Platt EA, et al. A Systematic Review of the Prevalence and Diagnostic Workup of PIK3CA Mutations in HR+\/HER2- Metastatic Breast Cancer. Int J Breast Cancer. 2020;2020:3759179.","journal-title":"Int J Breast Cancer"},{"key":"1391_CR12","doi-asserted-by":"publisher","first-page":"4452","DOI":"10.1200\/JCO.2010.34.4879","volume":"29","author":"TW Miller","year":"2011","unstructured":"Miller TW, Balko JM, Arteaga CL. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol. 2011;29:4452\u201361.","journal-title":"J Clin Oncol"},{"key":"1391_CR13","doi-asserted-by":"publisher","first-page":"3803","DOI":"10.1200\/JCO.2014.59.0018","volume":"34","author":"PM LoRusso","year":"2016","unstructured":"LoRusso PM. Inhibition of the PI3K\/AKT\/mTOR Pathway in Solid Tumors. J Clin Oncol. 2016;34:3803\u201315.","journal-title":"J Clin Oncol"},{"key":"1391_CR14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13058-020-01284-9","volume":"22","author":"O Mart\u00ednez-S\u00e1ez","year":"2020","unstructured":"Mart\u00ednez-S\u00e1ez O, Chic N, Pascual T, Adamo B, Vidal M, Gonz\u00e1lez-Farr\u00e9 B, et al. Frequency and spectrum of PIK3CA somatic mutations in breast cancer. Breast Cancer Res. 2020;22:45.","journal-title":"Breast Cancer Res"},{"key":"1391_CR15","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1186\/s12885-022-10078-5","volume":"22","author":"M Fillbrunn","year":"2022","unstructured":"Fillbrunn M, Signorovitch J, Andr\u00e9 F, Wang I, Lorenzo I, Ridolfi A, et al. PIK3CA mutation status, progression and survival in advanced HR + \/HER2- breast cancer: a meta-analysis of published clinical trials. BMC Cancer. 2022;22:1002.","journal-title":"BMC Cancer"},{"key":"1391_CR16","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.ccell.2020.03.009","volume":"37","author":"AB Hanker","year":"2020","unstructured":"Hanker AB, Sudhan DR, Arteaga CL. Overcoming Endocrine Resistance in Breast Cancer. Cancer Cell. 2020;37:496\u2013513.","journal-title":"Cancer Cell"},{"key":"1391_CR17","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1200\/JCO.2017.74.8301","volume":"36","author":"D Zardavas","year":"2018","unstructured":"Zardavas D, Te Marvelde L, Milne RL, Fumagalli D, Fountzilas G, Kotoula V, et al. Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data. J Clin Oncol. 2018;36:981\u201390.","journal-title":"J Clin Oncol"},{"key":"1391_CR18","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","volume":"380","author":"F Andr\u00e9","year":"2019","unstructured":"Andr\u00e9 F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019;380:1929\u201340.","journal-title":"N Engl J Med"},{"key":"1391_CR19","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1056\/NEJMoa2404625","volume":"391","author":"NC Turner","year":"2024","unstructured":"Turner NC, Im SA, Saura C, Juric D, Loibl S, Kalinsky K, et al. Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer. N Engl J Med. 2024;391:1584\u201396.","journal-title":"N Engl J Med"},{"key":"1391_CR20","doi-asserted-by":"crossref","unstructured":"Turner NC, Im S-A, Saura C, Juric D, Loibl S, Kalinsky K, et al. INAVO120: Phase III trial final overall survival (OS) analysis of first-line inavolisib (INAVO)\/placebo (PBO)+ palbociclib (PALBO)+ fulvestrant (FULV) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR+), HER2-negative (HER2\u2013), endocrine-resistant advanced breast cancer (aBC). Am Soc Clin Oncol. 2025.","DOI":"10.1200\/JCO.2025.43.16_suppl.1003"},{"key":"1391_CR21","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","volume":"388","author":"NC Turner","year":"2023","unstructured":"Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, et al. Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2023;388:2058\u201370.","journal-title":"N Engl J Med"},{"key":"1391_CR22","doi-asserted-by":"crossref","unstructured":"Chia SK, Redfern AD, Ayoub J-PM, Chalchal HI, Rayson D, Rushton M, et al. A double-blind placebo controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for advanced HER2-negative and estrogen receptor positive (ER+) breast cancer following progression on first line CDK 4\/6 inhibitor and aromatase inhibitor: The CCTG\/BCT MA. 40\/FINER study (NCT04650581). Am Soc Clin Oncol. 2025.","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA1005"},{"key":"1391_CR23","doi-asserted-by":"crossref","unstructured":"Manich CS, Carey L, Curigliano G, Harbeck N, O\u2019Shaughnessy J, Bidard F et al. 297O Imlunestrant (Imlu) with or without abemaciclib (Abema) in advanced breast cancer (ABC): A subgroup analysis in CDK4\/6 inhibitor (CDK4\/6i)-pretreated patients (pts) from EMBER-3. ESMO Open. 2025;10:104869.","DOI":"10.1016\/j.esmoop.2025.104869"},{"key":"1391_CR24","doi-asserted-by":"publisher","first-page":"e629","DOI":"10.1016\/S1470-2045(24)00673-9","volume":"25","author":"HS Rugo","year":"2024","unstructured":"Rugo HS, Lerebours F, Ciruelos E, Drullinsky P, Ruiz-Borrego M, Neven P, et al. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4\/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncol. 2024;25:e629\u201338.","journal-title":"Lancet Oncol"},{"key":"1391_CR25","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1200\/JCO.20.03565","volume":"39","author":"DP McDonnell","year":"2021","unstructured":"McDonnell DP, Wardell SE, Chang CY, Norris JD. Next-Generation Endocrine Therapies for Breast Cancer. J Clin Oncol. 2021;39:1383\u20138.","journal-title":"J Clin Oncol"},{"key":"1391_CR26","doi-asserted-by":"publisher","first-page":"102432","DOI":"10.1016\/j.ctrv.2022.102432","volume":"109","author":"E Ferraro","year":"2022","unstructured":"Ferraro E, Walsh EM, Tao JJ, Chandarlapaty S, Jhaveri K. Accelerating drug development in breast cancer: New frontiers for ER inhibition. Cancer Treat Rev. 2022;109:102432.","journal-title":"Cancer Treat Rev"},{"key":"1391_CR27","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1016\/S1470-2045(24)00387-5","volume":"25","author":"M Oliveira","year":"2024","unstructured":"Oliveira M, Pominchuk D, Nowecki Z, Hamilton E, Kulyaba Y, Andabekov T, et al. Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial. Lancet Oncol. 2024;25:1424\u201339.","journal-title":"Lancet Oncol"},{"key":"1391_CR28","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1056\/NEJMoa2502929","volume":"393","author":"FC Bidard","year":"2025","unstructured":"Bidard FC, Mayer EL, Park YH, Janni W, Ma C, Cristofanilli M, et al. First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer. N Engl J Med. 2025;393:569\u201380.","journal-title":"N Engl J Med"},{"key":"1391_CR29","doi-asserted-by":"publisher","first-page":"110452","DOI":"10.1016\/j.mce.2019.110452","volume":"493","author":"JJ Flanagan","year":"2019","unstructured":"Flanagan JJ, Neklesa TK. Targeting Nuclear Receptors with PROTAC degraders. Mol Cell Endocrinol. 2019;493:110452.","journal-title":"Mol Cell Endocrinol"},{"key":"1391_CR30","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1080\/14796694.2024.2377530","volume":"20","author":"EP Hamilton","year":"2024","unstructured":"Hamilton EP, Ma C, De Laurentiis M, Iwata H, Hurvitz SA, Wander SA, et al. VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+\/HER2- advanced breast cancer. Future Oncol. 2024;20:2447\u201355.","journal-title":"Future Oncol"},{"key":"1391_CR31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/1538-7445.SABCS23-PO3-05-08","volume":"84","author":"S Hurvitz","year":"2024","unstructured":"Hurvitz S, Schott A, Ma C, Nanda R, Zahrah G, Hunter N, et al. Abstract PO3-05-08: Updated results from VERITAC evaluating vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, in ER\u2013positive\/human epidermal growth factor receptor 2 (HER2)\u2013negative advanced breast cancer. Cancer Res. 2024;84:3\u20138. PO3-05-8-PO.","journal-title":"Cancer Res"},{"key":"1391_CR32","doi-asserted-by":"crossref","unstructured":"Hamilton EP, De Laurentiis M, Jhaveri KL, Hu X, Ladoire S, Patsouris A, et al. Vepdegestrant, a PROTAC estrogen receptor (ER) degrader, vs fulvestrant in ER-positive\/human epidermal growth factor receptor 2 (HER2)\u2013negative advanced breast cancer: Results of the global, randomized, phase 3 VERITAC-2 study. Am Soc Clin Oncol. 2025.","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA1000"},{"key":"1391_CR33","doi-asserted-by":"crossref","unstructured":"Borges V, Chien J, Nunnery S, Mouabbi J, Ma C, Bahadur S et al. 212P A phase Ib\/II study of palazestrant (OP-1250) in combination with ribociclib in patients with estrogen receptor-positive human epidermal growth factor receptor 2-negative (ER+, HER2-) metastatic breast cancer. ESMO Open. 2024;9:103234.","DOI":"10.1016\/j.esmoop.2024.103234"},{"key":"1391_CR34","doi-asserted-by":"publisher","first-page":"S338","DOI":"10.1016\/j.annonc.2023.09.559","volume":"34","author":"N Lin","year":"2023","unstructured":"Lin N, Borges V, Patel M, Okera M, Meisel J, Wesolowski R, et al. 382MO Updated results from the phase I\/II study of OP-1250, an oral complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) in patients (pts) with advanced or metastatic ER-positive, HER2-negative breast cancer. Ann Oncol. 2023;34:S338.","journal-title":"Ann Oncol"},{"key":"1391_CR35","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1200\/JCO.23.01500","volume":"42","author":"M Mart\u00edn","year":"2024","unstructured":"Mart\u00edn M, Lim E, Chavez-MacGregor M, Bardia A, Wu J, Zhang Q, et al. Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study. J Clin Oncol. 2024;42:2149\u201360.","journal-title":"J Clin Oncol"},{"key":"1391_CR36","doi-asserted-by":"publisher","first-page":"4014","DOI":"10.1200\/JCO.22.02746","volume":"41","author":"SM Tolaney","year":"2023","unstructured":"Tolaney SM, Chan A, Petrakova K, Delaloge S, Campone M, Iwata H, et al. AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. J Clin Oncol. 2023;41:4014\u201324.","journal-title":"J Clin Oncol"},{"key":"1391_CR37","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/j.annonc.2023.09.3103","volume":"34","author":"S Damodaran","year":"2023","unstructured":"Damodaran S, O\u2019Sullivan CC, Elkhanany A, Anderson IC, Barve M, Blau S, et al. Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+\/HER2- breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2. Ann Oncol. 2023;34:1131\u201340.","journal-title":"Ann Oncol"},{"key":"1391_CR38","doi-asserted-by":"crossref","unstructured":"Goetz MP, Wander SA, Bachelot T, Batist G, Cortes J, Cristofanilli M, et al. Open-label, randomized, multicenter, phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclib for treating ER+\/HER2-, locally advanced or metastatic breast cancer with an ESR1 mutation. Am Soc Clin Oncol. 2024.","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS1127"},{"key":"1391_CR39","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1056\/NEJMra1704560","volume":"379","author":"MD Goncalves","year":"2018","unstructured":"Goncalves MD, Hopkins BD, Cantley LC. Phosphatidylinositol 3-Kinase, Growth Disorders, and Cancer. N Engl J Med. 2018;379:2052\u201362.","journal-title":"N Engl J Med"},{"key":"1391_CR40","doi-asserted-by":"crossref","unstructured":"Saura C, Sammons SL, Bergamino M, Schott A, Italiano A, Wisinski KB et al. Abstract PS7-01: Efficacy of RLY-2608, a mutant-selective PI3K\u03b1 inhibitor in patients with PIK3CA-mutant HR+ HER2-advanced breast cancer: ReDiscover trial. Clin Cancer Res. 2025;31:PS7-01-PS7-.","DOI":"10.1158\/1557-3265.SABCS24-PS7-01"},{"key":"1391_CR41","doi-asserted-by":"crossref","unstructured":"Juric D, Giordano A, Jhaveri K, Munster P, Ahnert JR, LoRusso P et al. Abstract PS7-02: First-in-human results of STX-478, a mutant-selective PI3K alpha inhibitor, in HR+ breast cancer and advanced solid tumor patients. Clin Cancer Res. 2025;31:PS7-02-PS7-.","DOI":"10.1158\/1557-3265.SABCS24-PS7-02"},{"key":"1391_CR42","doi-asserted-by":"crossref","unstructured":"Agresta S, Spira A, Varkaris A, Im S-A, Kabos P, Yarza R et al. Abstract P3-08-19: Preliminary results from PIKture-01, a First-in-Human Study of OKI-219, a mutant selective inhibitor of PI3K\u03b1-H1047R, in mutant selected solid tumors including breast cancer. Clin Cancer Res. 2025;31:P3-08-19-P3-08-19.","DOI":"10.1158\/1557-3265.SABCS24-P3-08-19"},{"key":"1391_CR43","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.ccell.2020.03.010","volume":"37","author":"M \u00c1lvarez-Fern\u00e1ndez","year":"2020","unstructured":"\u00c1lvarez-Fern\u00e1ndez M, Malumbres M. Mechanisms of Sensitivity and Resistance to CDK4\/6 Inhibition. Cancer Cell. 2020;37:514\u201329.","journal-title":"Cancer Cell"},{"key":"1391_CR44","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1158\/0008-5472.CAN-21-2428","volume":"82","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Golomb L, Meyerson M. Functional Genomic Analysis of CDK4 and CDK6 Gene Dependency across Human Cancer Cell Lines. Cancer Res. 2022;82:2171\u201384.","journal-title":"Cancer Res"},{"key":"1391_CR45","doi-asserted-by":"crossref","unstructured":"Palmer CL, Boras B, Pascual B, Li N, Li D, Garza S et al. CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety. Cancer Cell. 2025;43:464\u2013481.","DOI":"10.1016\/j.ccell.2025.02.006"},{"key":"1391_CR46","doi-asserted-by":"crossref","unstructured":"Wander S, Valacer D, Zuniga R, Yeckes-Rodin H, Perkins C, Ge L et al. Abstract PO3-18-06: First-in-human phase 1A study of RGT-419B, a next generation CDK4 inhibitor, in patients (pts) with hormone receptor positive (HR+) HER2-advanced\/metastatic breast cancer (ABC) who progressed on prior CDK4\/6 inhibitors (CDK4\/6i). Cancer Res. 2024;84:PO3-18-06-PO3-18-06.","DOI":"10.1158\/1538-7445.SABCS23-PO3-18-06"},{"key":"1391_CR47","doi-asserted-by":"crossref","unstructured":"Giordano A, Sharma M, Williams A, Schmid P, Flores Diaz DF, Magallanes M, et al. First-in-human phase 1\/2a study of the first-in-class, next-generation CDK4-selective inhibitor PF-07220060\u2009+\u2009endocrine therapy (ET): Updated safety data in patients with HR+\/HER2\u2009\u2013\u2009mBC. Am Soc Clin Oncol. 2024.","DOI":"10.1200\/JCO.2024.42.16_suppl.3108"},{"key":"1391_CR48","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.ccell.2018.11.006","volume":"34","author":"Z Li","year":"2018","unstructured":"Li Z, Razavi P, Li Q, Toy W, Liu B, Ping C, et al. Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4\/6 Inhibitors via the Hippo Pathway. Cancer Cell. 2018;34:893\u2013e9058.","journal-title":"Cancer Cell"},{"key":"1391_CR49","doi-asserted-by":"publisher","first-page":"3356","DOI":"10.1038\/s41467-021-23612-z","volume":"12","author":"LR Pack","year":"2021","unstructured":"Pack LR, Daigh LH, Chung M, Meyer T. Clinical CDK4\/6 inhibitors induce selective and immediate dissociation of p21 from cyclin D-CDK4 to inhibit CDK2. Nat Commun. 2021;12:3356.","journal-title":"Nat Commun"},{"key":"1391_CR50","doi-asserted-by":"crossref","unstructured":"Gomes I, Abreu C, Costa L, Casimiro S. The evolving pathways of the efficacy of and resistance to CDK4\/6 inhibitors in breast cancer. Cancers (Basel). 2023;1(19):4835.","DOI":"10.3390\/cancers15194835"},{"key":"1391_CR51","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1158\/2159-8290.CD-23-0954","volume":"14","author":"C Dietrich","year":"2024","unstructured":"Dietrich C, Trub A, Ahn A, Taylor M, Ambani K, Chan KT, et al. INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors. Cancer Discov. 2024;14:446\u201367.","journal-title":"Cancer Discov"},{"key":"1391_CR52","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","volume":"379","author":"NC Turner","year":"2018","unstructured":"Turner NC, Slamon DJ, Ro J, Bondarenko I, Im SA, Masuda N, et al. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. N Engl J Med. 2018;379:1926\u201336.","journal-title":"N Engl J Med"},{"key":"1391_CR53","doi-asserted-by":"crossref","unstructured":"Kudo R, Safonov A, Jones C, Moiso E, Dry JR, Shao H, et al. Long-term breast cancer response to CDK4\/6 inhibition defined by TP53-mediated geroconversion. Cancer Cell. 2024;42:1919-35.e9.","DOI":"10.1016\/j.ccell.2024.09.009"},{"key":"1391_CR54","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","volume":"375","author":"GN Hortobagyi","year":"2016","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med. 2016;375:1738\u201348.","journal-title":"N Engl J Med"},{"key":"1391_CR55","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1056\/NEJMoa2114663","volume":"386","author":"GN Hortobagyi","year":"2022","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Hart L, et al. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. N Engl J Med. 2022;386:942\u201350.","journal-title":"N Engl J Med"},{"key":"1391_CR56","doi-asserted-by":"crossref","unstructured":"Yap TA, Elhaddad AM, Grisham RN, Hamm JT, Marks DK, Shapiro G, et al. First-in-human phase 1\/2a study of a potent and novel CDK2-selective inhibitor PF-07104091 in patients (pts) with advanced solid tumors, enriched for CDK4\/6 inhibitor resistant HR+\/HER2-breast cancer. Am Soc Clin Oncol. 2023.","DOI":"10.1200\/JCO.2023.41.16_suppl.3010"},{"key":"1391_CR57","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1016\/j.cell.2023.05.013","volume":"186","author":"M Arora","year":"2023","unstructured":"Arora M, Moser J, Hoffman TE, Watts LP, Min M, Musteanu M, et al. Rapid adaptation to CDK2 inhibition exposes intrinsic cell-cycle plasticity. Cell. 2023;186:2628\u2013e4321.","journal-title":"Cell"},{"key":"1391_CR58","doi-asserted-by":"publisher","first-page":"S495","DOI":"10.1016\/j.annonc.2024.08.685","volume":"35","author":"T Yap","year":"2024","unstructured":"Yap T, Yan F, Sadeghi S, Lin T, Liu F, Malky L, et al. 618MO Phase Ib\/II first-in-class novel combination trial of next generation CDK4-selective inhibitor PF-07220060 and next generation CDK2-selective inhibitor PF-07104091 in HR+ HER2-metastatic breast cancer and advanced solid tumors. Ann Oncol. 2024;35:S495\u20136.","journal-title":"Ann Oncol"},{"key":"1391_CR59","doi-asserted-by":"crossref","unstructured":"Yap TA, Goldman JW, Vinayak S, Tomova A, Hamilton E, Naito Y et al. First-in-Human Phase I\/IIa Study of the First-in-Class CDK2\/4\/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer. Clin Cancer Res. 2025;31(14):2899\u20132909.","DOI":"10.1158\/1078-0432.CCR-24-2740"},{"key":"1391_CR60","doi-asserted-by":"crossref","unstructured":"Sharma S, Chung CY, Uryu S, Petrovic J, Cao J, Rickard A et al. Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A\/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancer. Cell Chem Biol. 2023;30(10):1191\u20131210.e20.","DOI":"10.1016\/j.chembiol.2023.07.005"},{"key":"1391_CR61","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1021\/acs.jmedchem.4c02613","volume":"68","author":"T Zheng","year":"2025","unstructured":"Zheng T, Wang S, Liu W, Lu Y. Targeting KAT6A\/B as a New Therapeutic Strategy for Cancer Therapy. J Med Chem. 2025;68:1002\u201320.","journal-title":"J Med Chem"},{"key":"1391_CR62","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.1038\/onc.2016.433","volume":"36","author":"L Yu","year":"2017","unstructured":"Yu L, Liang Y, Cao X, Wang X, Gao H, Lin SY, et al. Identification of MYST3 as a novel epigenetic activator of ER\u03b1 frequently amplified in breast cancer. Oncogene. 2017;36:2910\u20138.","journal-title":"Oncogene"},{"key":"1391_CR63","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/s41586-018-0387-5","volume":"560","author":"JB Baell","year":"2018","unstructured":"Baell JB, Leaver DJ, Hermans SJ, Kelly GL, Brennan MS, Downer NL, et al. Inhibitors of histone acetyltransferases KAT6A\/B induce senescence and arrest tumour growth. Nature. 2018;560:253\u20137.","journal-title":"Nature"},{"key":"1391_CR64","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.neo.2014.07.007","volume":"16","author":"B Turner-Ivey","year":"2014","unstructured":"Turner-Ivey B, Guest ST, Irish JC, Kappler CS, Garrett-Mayer E, Wilson RC, et al. KAT6A, a chromatin modifier from the 8p11-p12 amplicon is a candidate oncogene in luminal breast cancer. Neoplasia. 2014;16:644\u201355.","journal-title":"Neoplasia"},{"key":"1391_CR65","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1038\/s41591-024-03060-0","volume":"30","author":"T Mukohara","year":"2024","unstructured":"Mukohara T, Park YH, Sommerhalder D, Yonemori K, Hamilton E, Kim SB, et al. Inhibition of lysine acetyltransferase KAT6 in ER(+)HER2(-) metastatic breast cancer: a phase 1 trial. Nat Med. 2024;30:2242\u201350.","journal-title":"Nat Med"},{"key":"1391_CR66","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1248\/cpb.c18-00744","volume":"67","author":"T Nakada","year":"2019","unstructured":"Nakada T, Sugihara K, Jikoh T, Abe Y, Agatsuma T. The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy. Chem Pharm Bull (Tokyo). 2019;67:173\u201385.","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"1391_CR67","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science. 1987;235:177\u201382.","journal-title":"Science"},{"key":"1391_CR68","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1126\/science.2470152","volume":"244","author":"DJ Slamon","year":"1989","unstructured":"Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707\u201312.","journal-title":"Science"},{"key":"1391_CR69","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1200\/JCO.19.02488","volume":"38","author":"P Tarantino","year":"2020","unstructured":"Tarantino P, Hamilton E, Tolaney SM, Cortes J, Morganti S, Ferraro E, et al. HER2-Low Breast Cancer: Pathological and Clinical Landscape. J Clin Oncol. 2020;38:1951\u201362.","journal-title":"J Clin Oncol"},{"key":"1391_CR70","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1158\/2159-8290.CD-22-0703","volume":"12","author":"P Tarantino","year":"2022","unstructured":"Tarantino P, Curigliano G, Tolaney SM. Navigating the HER2-Low Paradigm in Breast Oncology: New Standards, Future Horizons. Cancer Discov. 2022;12:2026\u201330.","journal-title":"Cancer Discov"},{"key":"1391_CR71","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1002\/cncr.34904","volume":"129","author":"AM Roy","year":"2023","unstructured":"Roy AM, Kumarasamy VM, Dhakal A, O\u2019Regan R, Gandhi S. A review of treatment options in HER2-low breast cancer and proposed treatment sequencing algorithm. Cancer. 2023;129:2773\u201388.","journal-title":"Cancer"},{"key":"1391_CR72","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med. 2022;387:9\u201320.","journal-title":"N Engl J Med"},{"key":"1391_CR73","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","volume":"391","author":"A Bardia","year":"2024","unstructured":"Bardia A, Hu X, Dent R, Yonemori K, Barrios CH, O\u2019Shaughnessy JA, et al. Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer. N Engl J Med. 2024;391:2110\u201322.","journal-title":"N Engl J Med"},{"key":"1391_CR74","doi-asserted-by":"crossref","unstructured":"Curigliano G, Hu X, Dent RA, Yonemori K, Barrios Sr CH, O\u2019Shaughnessy J, et al. Trastuzumab deruxtecan (T-DXd) vs physician\u2019s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06). Am Soc Clin Oncol. 2024.","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA1000"},{"key":"1391_CR75","doi-asserted-by":"crossref","unstructured":"Dent RA, Curigliano G, Hu X, Yonemori K, Barrios CH, Wildiers H, et al. Exploratory biomarker analysis of trastuzumab deruxtecan (T-DXd) vs physician\u2019s choice of chemotherapy (TPC) in HER2-low\/ultralow, hormone receptor\u2013positive (HR+) metastatic breast cancer (mBC) in DESTINY-Breast06 (DB-06). Am Soc Clin Oncol. 2025.","DOI":"10.1200\/JCO.2025.43.16_suppl.1013"},{"key":"1391_CR76","doi-asserted-by":"publisher","first-page":"175883592091598","DOI":"10.1177\/1758835920915980","volume":"12","author":"A Nagayama","year":"2020","unstructured":"Nagayama A, Vidula N, Ellisen L, Bardia A. Novel antibody-drug conjugates for triple negative breast cancer. Ther Adv Med Oncol. 2020;12:1758835920915980.","journal-title":"Ther Adv Med Oncol"},{"key":"1391_CR77","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1021\/acs.bioconjchem.5b00223","volume":"26","author":"TM Cardillo","year":"2015","unstructured":"Cardillo TM, Govindan SV, Sharkey RM, Trisal P, Arrojo R, Liu D, et al. Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2\/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers. Bioconjug Chem. 2015;26:919\u201331.","journal-title":"Bioconjug Chem"},{"key":"1391_CR78","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","volume":"402","author":"HS Rugo","year":"2023","unstructured":"Rugo HS, Bardia A, Marm\u00e9 F, Cort\u00e9s J, Schmid P, Loirat D, et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;402:1423\u201333.","journal-title":"Lancet"},{"key":"1391_CR79","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1200\/JCO.22.01002","volume":"40","author":"HS Rugo","year":"2022","unstructured":"Rugo HS, Bardia A, Marm\u00e9 F, Cortes J, Schmid P, Loirat D, et al. Sacituzumab Govitecan in Hormone Receptor-Positive\/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer. J Clin Oncol. 2022;40:3365\u201376.","journal-title":"J Clin Oncol"},{"key":"1391_CR80","doi-asserted-by":"crossref","unstructured":"Bardia A, Jhaveri K, Im S-A, De Laurentiis M, Xu B, Pernas S, et al. Abstract GS02-01: randomized phase 3 study of datopotamab deruxtecan vs chemotherapy for patients with previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative breast cancer: results from TROPION-Breast01. Cancer Res. 2024;84:GS02-1-GS-1.","DOI":"10.1158\/1538-7445.SABCS23-GS02-01"},{"key":"1391_CR81","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.annonc.2025.01.009","volume":"36","author":"B Pistilli","year":"2025","unstructured":"Pistilli B, Jhaveri K, Im S, Simon SP, De Laurentiis M, Wang S, et al. VP1-2025: Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+\/HER2\u2013) breast cancer (BC): Final overall survival (OS) from the phase III TROPION-Breast01 trial. Ann Oncol. 2025;36:348\u201350.","journal-title":"Ann Oncol"},{"key":"1391_CR82","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1200\/JCO.24.00920","volume":"43","author":"A Bardia","year":"2025","unstructured":"Bardia A, Jhaveri K, Im SA, Pernas S, De Laurentiis M, Wang S, et al. Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable\/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01. J Clin Oncol. 2025;43:285\u201396.","journal-title":"J Clin Oncol"},{"key":"1391_CR83","doi-asserted-by":"crossref","unstructured":"Jhaveri K, Bardia A, Im S, Simon SP, De Laurentiis M, Wang S, et al. LBA2 Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in pretreated, inoperable\/metastatic HR+\/HER2\u2013breast cancer (BC): Additional safety analysis from TROPION-Breast01. ESMO Open. 2024;9:03479.","DOI":"10.1016\/j.esmoop.2024.103479"},{"key":"1391_CR84","doi-asserted-by":"crossref","unstructured":"Abelman RO, Spring L, Fell G, Davis A, Hensing W, Ryan P, et al. Abstract PS08-03: Sequencing antibody-drug conjugate after antibody-drug conjugate in metastatic breast cancer (A3 study): Multi-institution experience and biomarker analysis. Cancer Res. 2024;84:PS08-3-PS-3.","DOI":"10.1158\/1538-7445.SABCS23-PS08-03"},{"key":"1391_CR85","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41523-025-00748-5","volume":"11","author":"LA Huppert","year":"2025","unstructured":"Huppert LA, Mahtani R, Fisch S, Dempsey N, Premji S, Raimonde A, et al. Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC). NPJ Breast Cancer. 2025;11:34.","journal-title":"NPJ Breast Cancer"},{"key":"1391_CR86","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/s41416-024-02766-9","volume":"131","author":"F Poumeaud","year":"2024","unstructured":"Poumeaud F, Morisseau M, Cabel L, Gon\u00e7alves A, Rivier C, Tr\u00e9dan O, et al. Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer. Br J Cancer. 2024;131:702\u20138.","journal-title":"Br J Cancer"},{"key":"1391_CR87","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1158\/1078-0432.CCR-24-2771","volume":"31","author":"RO Abelman","year":"2025","unstructured":"Abelman RO, Wu B, Barnes H, Medford A, Norden B, Putur A, et al. TOP1 Mutations and Cross-Resistance to Antibody-Drug Conjugates in Patients with Metastatic Breast Cancer. Clin Cancer Res. 2025;31:1966\u201374.","journal-title":"Clin Cancer Res"},{"key":"1391_CR88","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1158\/2159-8290.CD-21-0702","volume":"11","author":"JT Coates","year":"2021","unstructured":"Coates JT, Sun S, Leshchiner I, Thimmiah N, Martin EE, McLoughlin D, et al. Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer. Cancer Discov. 2021;11:2436\u201345.","journal-title":"Cancer Discov"},{"key":"1391_CR89","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","volume":"21","author":"K Tsuchikama","year":"2024","unstructured":"Tsuchikama K, Anami Y, Ha SYY, Yamazaki CM. Exploring the next generation of antibody-drug conjugates. Nat Rev Clin Oncol. 2024;21:203\u201323.","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-026-01391-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-026-01391-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-026-01391-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:21:28Z","timestamp":1781648488000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-026-01391-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,18]]},"references-count":89,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["1391"],"URL":"https:\/\/doi.org\/10.1007\/s11864-026-01391-3","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,18]]},"assertion":[{"value":"19 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research Involving Human Participants and\/or Animals"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}